




UNIVERSITÀ
DEGLI STUDI
DI MILANO



Fondazione IRCCS Ca' Granda
Ospedale Maggiore Policlinico

Istituto Socio Sanitario



Graves' Orbitopathy Center – 20th Year Anniversary

UP TO DATE ON

Thyroid eye disease

NOVEL INSIGHTS
AND TREATMENT

Milan

September 8-9, 2023



UP TO DATE ON

Thyroid eye disease

NOVEL INSIGHTS AND TREATMENT



Scientific Committee:

Endocrinology

Mario Salvi

Maura Arosio

Giovanna Mantovani

Ilaria Muller

Otolaryngology

Lorenzo Pignataro

Claudio Guastella

Ophthalmology

Francesco Viola

Nicola Currò

Congress venue

Aula Granelli

Padiglione Granelli-Marcora

Policlinico, Ospedale Maggiore

Via Francesco Sforza 35 - Milano



Registration

Participation is free.

For logistical and organizational reasons, please fill out the form to confirm your participation.



[Click here to register](#)



UP TO DATE ON

Thyroid eye disease

NOVEL INSIGHTS AND TREATMENT

Program

Friday, September 8th

2.00 pm Welcoming address and presentation of the Symposium

The role of microbiota in Graves' disease and associated orbitopathy

2.30 pm Experimental evidence from a mouse model of TED
Giulia Masetti (IT)

2.50 pm Evidence in humans - *Marian Ludgate (UK)*

Blockade of the IGF-1 receptor: studies with linsitinib

3.10 pm Linsitinib treatment in a mouse model of TED
Anja Eckstein (DE)

3.30 pm The VGN-TED 301 trial: an update
Raymond Douglas (US)

3.50 pm *Coffee break*

Anti-TSHr blockade and novel immunosuppressants in active TED

4.20 pm K1-70 targeting of the TSH receptor - *Jane Sanders (UK)*

4.40 pm Belimumab (anti-BAFF) in active TED - *Irene Campi (IT)*

4.55 pm Rationale and efficacy of Sirolimus treatment in TED
Michele Marinò (IT)

Ongoing Randomized Controlled Trials in TED

5.10 pm The IMVT-1401-3201/3203 trials: rationale and preliminary data - *George Kahaly (DE)*

5.30 pm Tocilizumab in active TED: the Italian multicenter trial
Ilaria Muller (IT)

5.50 pm The VRDN - 001 clinical trial: an update
Raymond Douglas (US)

6.10 pm Discussion and conclusion





Saturday, September 9th

8.50 am Reconvening of the Symposium

Teprotumumab in TED: clinical and experimental data

9.00 am Experience with Teprotumumab in a US thyroid/eye clinic
Crysoula Dosiu (US)

9.20 am Teprotumumab in chronic disease?
Andrea Kossler (US)

9.40 am The safety profile of Teprotumumab - *Marius Stan (US)*

Assessment of treatment outcomes in TED: are the tools of the trade fit for purpose?

10.00 am Outcomes of efficacy: inflammation, proptosis or both?
Luigi Bartalena (IT), Marius Stan (US), Petros Perros (UK)

10.40 am Coffee break

Update on the surgical treatment of TED

11.00 am Endoscopic orbital surgery for dysthyroid optic neuropathy - *Claudio Guastella (IT)*

11.20 am Ophthalmological/surgical integrated management of dysthyroid optic neuropathy - *Nicola Currò (IT)*

11.35 am Neuronavigation in orbital surgery - *Lelio Baldeschi (IT)*

Round table Prevention of TED

11.50 am Preventable risk factors - *Maria Laura Tanda (IT)*

12.00 pm The TEARS proposal
*Lelio Baldeschi (IT), Anja Eckstein (DE),
Petros Perros (UK)*

12.20 pm The Milan Pledge - *Mario Salvi (IT)*

12.30 pm Concluding remarks



UP TO DATE ON

Thyroid eye disease

NOVEL INSIGHTS AND TREATMENT



Faculty

Lelio Baldeschi (IT)

Luigi Bartalena (IT)

Irene Campi (IT)

Nicola Currò (IT)

Crysoula Dosiu (US)

Raymond Douglas (US)

Anja Eckstein (DE)

Claudio Guastella (IT)

George Kahaly (DE)

Andrea Kossler (US)

Marian Ludgate (UK)

Giulia Masetti (IT)

Michele Marinò (IT)


Ilaria Muller (IT)

Petros Perros (UK)

Jane Sanders (UK)

Marius Stan (US)

Maria Luisa Tanda (IT)



UP TO DATE ON

Thyroid eye disease

NOVEL INSIGHTS AND TREATMENT



With the unconditional contribution of



Caring Innovation



Segreteria Organizzativa

FASI s.r.l.
Via O. Tommasini 7 | 00162 Roma
Tel. 06 97605616 | Fax 06 97605650
v.toti@fasiweb.com | www.fasiweb.com

